

Cytosorbents Corp
Form 8-K
July 31, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2012

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada **000-51038** **98-0373793**

(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

7 Deer Park Drive, Suite K

Monmouth Junction, New Jersey 08852

Edgar Filing: Cytosorbents Corp - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(732) 329-8885**

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written
communications
..pursuant to Rule
425 under the
Securities Act (17
CFR 230.425)

Soliciting material
pursuant to Rule
14a-12 under the
Exchange Act (17
CFR 240.14a-12)

Pre-commencement
communications
..pursuant to Rule
14d-2(b) under the
Exchange Act (17
CFR 240.14d-2(b))

Pre-commencement
communications
..pursuant to Rule
13e-4(c) under the
Exchange Act (17
CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On July 25, 2012, CytoSorbents Corporation (the “Company”) sent an email to various shareholders and other company contacts announcing that Brean Murray, Carret & Co. (“Brean Murray”), a boutique investment bank dedicated to small cap and emerging growth companies, initiated analyst research coverage on the Company on July 24, 2012, with a “Buy” rating.

Anyone interested in obtaining a copy of the report prepared by Brean Murray may contact info@cytosorbents.com for additional details.

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 31, 2012 CytoSorbents Corporation

By: /s/ Dr. Phillip P. Chan
Name: Dr. Phillip P.
Chan
Title: President and
CEO